Abstract:Background:
Environmental chemicals may be associated with endometriosis. No published research has focused on the possible role of perfluorochemicals (PFCs) despite their widespread presence in human tissues.
Methods:
We formulated two samples. The first was an operative sample comprising 495 women aged 18–44 years scheduled for laparoscopy/laparotomy at one of 14 participating clinical sites in the Salt Lake City or San Francisco area, 2007–2009. The second was a population-based sample comprising 131 wome… Show more
“…Therefore, to the extent that PFASs impact circulating ovarian hormone levels, they may have profound effects on women's health and well-being. Researchers have begun to examine PFASs in relation to some of these outcomes, including endometriosis (75) and breast cancer (33, 76), however further study is clearly needed, as is more research on the underlying mechanisms.…”
Objective
To examine associations between environmental exposure to perfluoroalkyl substances (PFASs) and ovarian hormone concentrations in naturally cycling women.
Design
Estradiol and progesterone were measured in saliva samples collected daily for a single menstrual cycle and concentrations of PFASs (including perfluoroctane sulfonate [PFOS] and perfluoroctanoic acid [PFOA]) were measured in serum samples collected during the same cycle.
Setting
Tromsø, Norway.
Patients
178 healthy, naturally cycling women, ages 25-35.
Intervention
None.
Main outcome measures(s)
Mean follicular estradiol (cycle days −7 to −1, where 0 is the day of ovulation); mean luteal progesterone (cycle days +2 to 10).
Results
Among nulliparous, but not parous women, PFOS concentrations were inversely associated with estradiol (β=−0.025, 95% CI: −0.043, −0.007) and progesterone (β=−0.027, 95% CI: −0.048, −0.007). Similar, but weaker results were observed for perfluorooctanesulfonic acid (PFOSA). No associations were observed between other PFASs (including PFOA) and ovarian steroid concentrations, nor were any associations noted in parous women.
Conclusions
Our results demonstrate that PFOS and PFOSA may be associated with decreased production of estradiol and progesterone in reproductive age women. These results suggest a possible mechanism by which PFASs affect women's health, and underscore the importance of parity in research on PFASs and women's reproductive health.
“…Therefore, to the extent that PFASs impact circulating ovarian hormone levels, they may have profound effects on women's health and well-being. Researchers have begun to examine PFASs in relation to some of these outcomes, including endometriosis (75) and breast cancer (33, 76), however further study is clearly needed, as is more research on the underlying mechanisms.…”
Objective
To examine associations between environmental exposure to perfluoroalkyl substances (PFASs) and ovarian hormone concentrations in naturally cycling women.
Design
Estradiol and progesterone were measured in saliva samples collected daily for a single menstrual cycle and concentrations of PFASs (including perfluoroctane sulfonate [PFOS] and perfluoroctanoic acid [PFOA]) were measured in serum samples collected during the same cycle.
Setting
Tromsø, Norway.
Patients
178 healthy, naturally cycling women, ages 25-35.
Intervention
None.
Main outcome measures(s)
Mean follicular estradiol (cycle days −7 to −1, where 0 is the day of ovulation); mean luteal progesterone (cycle days +2 to 10).
Results
Among nulliparous, but not parous women, PFOS concentrations were inversely associated with estradiol (β=−0.025, 95% CI: −0.043, −0.007) and progesterone (β=−0.027, 95% CI: −0.048, −0.007). Similar, but weaker results were observed for perfluorooctanesulfonic acid (PFOSA). No associations were observed between other PFASs (including PFOA) and ovarian steroid concentrations, nor were any associations noted in parous women.
Conclusions
Our results demonstrate that PFOS and PFOSA may be associated with decreased production of estradiol and progesterone in reproductive age women. These results suggest a possible mechanism by which PFASs affect women's health, and underscore the importance of parity in research on PFASs and women's reproductive health.
“…Trabert et al [25] 251:538 PCBs 18,28,44,49,52,66,74,87,99,101,118,128,138,146,149,151,153,156,157,167,170,172,177,178,180,183,187,189,194,195,196,201,206 Buck-Louis et al [27] 190:283 and 14:113…”
Section: Polychlorinated Biphenyls (Pcbs) Dioxin and Dioxin-like Commentioning
Endometriosis is widely acknowledged to be an estrogen dependent disease or unknown etiology. Recognition that environmental toxicants can bind with and activate the estrogen receptor, dysregulate steroid metabolism and, in some cases, act as anti-androgenic substances (phthalate esters) has led to proposal that exposure to environmental toxicants are associated with increased risk of endometriosis. Since our last review of the subject in 2008, the literature has expanded with several epidemiological and biomonitoring studies suggesting a potential association, whereas others have been unable to demonstrate a link between exposure and enhanced risk. Therefore, we carried out a systematic review and critical appraisal of the literature published over the past decade (2009-2019). The majority of studies found dealt with exposure to polychlorinated biphenyls (PCBs), dioxins, dioxin-like and non-dioxin-like compounds, bisphenol A and phthalate esters. Several studies suggest a potential association between exposure to environmental toxicants; however, important weaknesses in study design, methodology, and analysis together with many contradictory studies weaken confidence in these associations. Consequently, we conclude that despite a growing literature, evidence for an association between exposure to environmental toxicants and risk of endometriosis remains weak.
“…Endometriosis is a common gynecologic condition that has been shown to be associated with POPs in a number of studies. 12,31,32 Further, in the operative cohort from this study, endometriosis was positively associated with gamma-HCH and inversely associated with PBDE 47, PCB 74 and PCB 156 measured in omental fat. We attempted to address the concern that the presence of other gynecologic conditions may be masking an underlying association between POPs and fibroids with our sensitivity analysis that excluded women with a postoperative diagnosis of endometriosis.…”
To evaluate the association between persistent organic pollutants (POPs) and uterine fibroids we used previously collected data from a cohort of women 18–44 years of age undergoing laparoscopy or laparotomy at 14 participating hospital surgical centers (n=473). POP concentrations were measured in omental fat and serum. Presence of fibroids was defined based on a postoperative diagnosis (n=99). Odds ratios (OR) and 95% confidence interval (CI) for each POP by biologic medium was estimated using unconditional logistic regression adjusted for identified covariates. Concentrations were higher in omental fat than in serum for all POPs. Serum p,p′-dichlorodiphenyldichloroethylene (p,p′-DDE) was the only POP associated with fibroids [per 1-SD increase in log-transformed p,p′-DDE OR (95% CI): 1.37 (1.05–1.80)]. In analyses excluding women diagnosed with endometriosis, a number of polychlorinated biphenyls (PCBs) measured in omental fat were associated with fibroids [PCB 99: 1.64 (1.08, 2.49); PCB 138: 1.64 (1.03, 2.59); PCB 146: 1.54 (1.01, 2.37); PCB 153: 1.88 (1.12, 3.13); PCB 196: 1.60 (1.02, 2.51); PCB 206: 1.52 (1.01, 2.29)]. Although exploratory, our study suggests that PCBs may be associated with fibroids in the absence of other gynecologic disorders such as endometriosis, but the associations varied by biologic media with more POPs emerging when quantified in fat.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.